828 results about "In vivo experiment" patented technology

The invention belongs to the technical field of biological medicines, and provides application of DRAM1 as a diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of a kit, a carrier and a medicine aiming at the problem of lack of effective treatment targets of NAFLD-related HCC. As a target spot for resisting the non-alcoholic fatty liver disease related hepatocellular carcinoma, the expression level of the DRAM1 in liver tissues of non-alcoholic fatty liver disease related hepatocellular carcinoma patients and mice is increased. According to the application disclosed by the invention, research is developed aiming at the effect of the DRAM1 in the generation and development of NAFLD-related HCC, the analysis of TCGA liver cancer queue data and a GSE164760 data set is taken as an entry point, the influence of the DRAM1 on the diagnosis and prognosis of the liver cancer is comprehensively analyzed, and verification is carried out through a mouse in-vivo experiment, so that a new thought and a new target spot are provided for clinical diagnosis and treatment of the liver cancer.

The invention provides an anticoagulant coating for medical instruments, which can be used in the field of regenerative medical instruments. The prepared anticoagulant coating has short-term and long-term anticoagulant performance, and in addition, the thrombin responsive nanoparticles wrapped in the hydrogel coating can selectively release a factor Xa (FXa) inhibitor apixaban according to needs, so that thrombosis is inhibited in the middle stage of implantation. In-vitro and in-vivo experimental evidences show that after the material is implanted for a long time, an organized endodermis can be seen on the surface of the material, and the material has a special antithrombotic characteristic. The dynamic adjusting system has a multi-layer protection mechanism, and a new thought can be provided for designing the surface of a contact blood material adapting to environmental conditions.

The invention discloses Klebsiella oxytoca G1-2-4 and application thereof, and particularly relates to application of the Klebsiella oxytoca G1-2-4 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.30986 in preparation of a biocontrol preparation or feed for preventing and treating aquatic diseases. The invention further discloses application of the Klebsiella oxytoca G1-2-4 in preparation of the biocontrol preparation or feed for preventing and treating the aquatic diseases and application of the Klebsiella oxytoca G1-2-4 in preparation of the biocontrol preparation or feed for preventing and treating the aquatic diseases. The invention relates to an application of klebsiella oxytoca G1-2-4 in inhibiting the growth of pseudomonas plecoglossicida and a biocontrol preparation or feed containing the klebsiella oxytoca G1-2-4 and used for preventing and treating aquatic diseases. According to the Klebsiella oxytoca cultured in an isolated mode, the disease resistance of the Klebsiella oxytoca is verified through in-vitro and in-vivo experiments, the disease resistance mechanism of the Klebsiella oxytoca is preliminarily explored, and reference is provided for research on prevention and treatment of the visceral white-spot disease of the small yellow croakers.

The invention relates to application of a tea exosome in preparation of a medicine for improving skin pigmentation, the tea exosome is creatively extracted and purified, and the tea exosome can effectively inhibit proliferation of melanoma cells and inhibit expression of melanin generation related protein by scavenging free radicals and inhibiting tyrosinase activity, so that the effect of improving skin pigmentation is achieved. The intracellular melanin removal is promoted. In a mouse in-vivo experiment, after the tea exosome is applied, it is observed that the skin epidermis thickness of a mouse is reduced, the dermis thickness is increased, collagen arrangement is tighter and more ordered, the content is increased, and meanwhile generation of inflammatory factors is reduced. The tea exosome can significantly increase the content of a melanin autophagy key factor LC3B and reduce the content of P62 to promote melanin autophagy, and has good percutaneous infiltration capacity, thereby playing a role in improving skin pigmentation.

The invention belongs to the technical field of medicines, and particularly discloses application of niclosamide in preparation of a medicine for treating epididymis and testis fibrosis caused by bacterial infection. A UPEG-mouse epididymis / orchitis model is firstly constructed, a result shows that a monocyte subset highly expressed by S100a4 appears in a testis, the group of cells mainly express CD11b monocyte characteristics in the early stage when entering the testis, and the group of cells are partially converted into F4 / 80 + and alpha-SMA + fibroblast characteristics in the later stage. A myeloid macrophage knockout mouse is used for constructing a UPEG-epididymis / orchitis model, and the fibrosis degree of testis and epididymis is obviously reduced; a molecular mechanism shows that S100a4 can strengthen a TGF beta-STAT3 signal channel to promote the transformation of macrophages to fibroblasts, and niclosamide can inhibit the process. Mouse in-vivo experiment results show that niclosamide can obviously inhibit UPEG-mouse epididymis and testis fibrosis.

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

The invention relates to the field of modified milk, in particular to pasteurized modified milk with a lead ion emission reduction function and application of the pasteurized modified milk. The pasteurized modified milk provided by the invention contains lactobacillus mucus fermentation B44, wherein the preservation number of the lactobacillus mucus fermentation B44 is CGMCC (China General Microbiological Culture Collection Center) No.17321. Compared with a control sample and other strains, the lactobacillus mucilaginosus B44 in the pasteurized modified milk provided by the invention can remarkably reduce the lead content in intestinal content supernatant, and results of in-vivo experiments of rats show that the lactobacillus mucilaginosus B44 can remarkably reduce the blood lead concentration, the lead content in livers and the lead content in kidneys of drinking objects, so that the lactobacillus mucilaginosus B44 can be used for preparing the pasteurized modified milk. The discharge of lead in excrement can be increased, and liver oxidative damage caused by lead poisoning can be effectively relieved, so that the method can be applied to research on in-vivo emission reduction of lead.

The invention provides a nanoparticle capable of releasing EGCG (epigallocatechin gallate) in response to ROS (reactive oxygen species) as well as a preparation method and application of the nanoparticle. The nanoparticles comprise a carrier and EGCG (epigallocatechin gallate) loaded on the carrier; the carrier is Prussian blue nanoparticles of which the surfaces are modified with polyethyleneimine and phenylboronic acid compounds. The preparation method of the nanoparticles is simple and easy to operate, the nanoparticles are good in dispersity, and through research, the nanoparticles have CAT-like, SOD-like and other multi-enzyme activities, can remove. OH, have a high EGCG drug loading rate and release EGCG in the presence of ROS. Besides, the nanoparticles show a good effect of improving myocardial ischemia reperfusion injury in cell level and rat in-vivo experiments, through comparison of EGCG and PB NPs single-drug treatment, synergistic treatment in the composite material achieves an effect of '1 + 1 > 2', and the composite material has good biological safety.

The invention relates to the technical field of aquaculture, in particular to nile tilapia ferritin, a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia ferritin is as shown in SEQ ID No.1, and the nile tilapia ferritin inhibits streptococcus agalactiae and / or aeromonas hydrophila. The invention provides Nile tilapia ferritin, and in-vitro experiments prove that the recombinant protein can effectively inhibit proliferation of pathogenic bacteria. A further in-vivo experiment research result shows that the ferritin heavy chain (Nile tilapia ferritin) has important functions of inhibiting pathogenic bacterium proliferation and improving the survival rate of an organism, and plays an important role in immune protection of the organism.

The invention discloses an anti-tumor medicine composition combined with a PARG inhibitor and application. Through natural product library screening and CCK-8 experiments, it is found that PARG knockout gastric cancer cells show significantly enhanced sensitivity to ginsenoside CK. Further clone formation experimental analysis shows that PARG knockout significantly enhances the inhibitory effect of ginsenoside CK on gastric cancer cell proliferation. In in-vivo experiments, a CDX model is utilized to verify that PARG knockout can significantly enhance the anti-tumor activity of ginsenoside CK on gastric cancer. The discovery provides an important experimental basis for clinical application of PARG as a gastric cancer treatment target and ginsenoside CK as a potential treatment drug. The research finds that the PARG inhibitor and ginsenoside CK are combined to achieve a better killing effect on other various cancer cells, and it is indicated that improvement of the effect is broad-spectrum.

The invention provides a camellia nitidissima plant endophytic bacterium as well as a fungicide and application thereof in resisting influenza A virus. The golden camellia plant endophytic bacteria are bacillus thuringiensis and are preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.32945. A fermentation product of the strain shows good antiviral activity in both in-vitro and in-vivo experiments, and can effectively inhibit replication of influenza viruses and protect infected mice from being damaged by lethal influenza viruses; the compound also shows the effect of regulating immune response, and the secretion of IFN-gamma is enhanced by down-regulating the secretion of proinflammatory factors such as IL-6 and IL-10, so that the immune resistance of the body is improved.

The invention relates to application of an MYZAP overexpression recombinant vector in preparation of a medicine for preventing and treating arrhythmia, and belongs to the technical field of biological medicines. In order to solve the problem that application of gene drugs in prevention and treatment of arrhythmia after myocardial infarction is limited, the invention provides application of a myocardial microbelt adhesion protein MYZAP overexpression recombinant vector in preparation of drugs for prevention and treatment of arrhythmia, and the MYZAP overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP of an overexpression MYZAP gene. In-vivo experiments prove that MYZAP overexpression can reduce the occurrence of arrhythmia after myocardial infarction by increasing the content of MYZAP protein in cardiac myocardial cells, and improve cardiac functions and cardiac electrical conduction disorders after myocardial infarction. On the basis, the invention further provides a medicine for preventing and treating arrhythmia after myocardial infarction, a new strategy is provided for gene therapy of arrhythmia after myocardial infarction, and the medicine has a wide clinical application prospect.

The composition is of a network structure and is composed of strontium ions and chlorogenic acid, and the weight ratio of the strontium ions to the chlorogenic acid is 1: (9-11). The composition and hydrogel are mixed to prepare a microneedle patch, and the microneedle patch is prepared into a medical instrument for wound repair. Through verification, the SrC-MPNs is continuously released by the SrC-MPNs (at) MN-PP, so that the substances are dissolved and absorbed into tissue fluid around a wound, and strontium ions and chlorogenic acid in the SrC-MPN can stably and continuously exert the effects of resisting bacteria and oxidation, promoting angiogenesis, promoting wound healing and the like. An in-vivo experiment result shows that the SrC-MPNs (at) MN-PP can promote in-vivo and in-vitro wound healing, promote M2 macrophage polarization, remove excessive ROS and promote angiogenesis and tissue regeneration so as to promote healing of diabetic wounds.

The invention relates to the technical field of medicines, and provides a lanosterol derivative as well as a preparation method and application thereof. The lanosterol derivative provided by the invention has a structural formula as shown in a formula I or a formula II. The lanosterol derivative provided by the invention has both fat solubility and water solubility, and can effectively permeate into a diseased region in a body, so that the medicinal availability is improved; results of the embodiment show that the solubility of the lanosterol derivative provided by the invention in water is obviously higher than that of lanosterol or 25-hydroxylanosterol, and the lanosterol derivative shows an obvious cataract treatment effect in animal in-vivo experiments and has a wide prospect in preparation of drugs for treating eye diseases or symptoms. # imgabs0 #

The provided long-acting kinin or the derivative thereof fundamentally solves the problem that kinin has no druggability, on one hand, the half-life period of kinin or the derivative thereof is prolonged through a long-acting technology, and it is prevented that kinin or the derivative thereof is rapidly degraded and inactivated in vivo; on the other hand, the action site of the kinin and the receptor is covered or partially covered through long-acting modification, so that the adverse reactions such as rapid blood pressure reduction and hypotension in a short time are effectively avoided. The long-acting kinin or the derivative thereof well retains receptor binding activity and signal transduction activity in an in-vitro cell experiment, can effectively treat hypertension and prevent or treat hypertension complications in an in-vivo experiment, and provides a new method for treating hypertension and hypertension complications.

The invention is applicable to the technical field of hydrogel, and provides dynamic cross-linked hydrogel and a preparation method and application thereof, and the preparation method comprises the following steps: cross-linking oxidized dextran and carboxymethyl chitosan containing phenylboronic acid modification groups; glucanase is added before the hydrogel is formed, and calcium peroxide nanoparticles coated with polydopamine are introduced; wherein the mass concentration of the oxidized dextran is 2-10% w / v, the mass concentration of the carboxymethyl chitosan containing the phenylboronic acid modified group is 2% w / v, the concentration of the glucanase is 10-100 U, and the concentration of the calcium peroxide nanoparticles coated with the polydopamine is 0.1-1% w / v. The hydrogel disclosed by the invention shows good cell compatibility, angiogenesis promoting capability and bioactivity for promoting dental pulp regeneration in multiple in-vitro and in-vivo experiments, is suitable for tissue engineering fields such as dental pulp injury repair and the like, and effectively solves the technical problem that conventional hydrogel is insufficient in cell survival support in three-dimensional culture and the like.

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The invention discloses application of an SUMO inhibitor 2-D08 in preparation of drugs for treating chronic myelogenous leukemia (CML) and drug resistance of a tyrosine kinase inhibitor (TKI) of the SUMO inhibitor 2-D08. It is revealed for the first time that SUMOylation modification drives disease progression by stabilizing BCR-ABL protein, 2-D08 promotes BCR-ABL protein degradation by inhibiting the modification, and leukemia cell proliferation is remarkably inhibited. In-vitro experiments prove that the compound effectively inhibits the activity of TKI drug-resistant cells, and in-vivo experiments show that 5 mg / kg of the compound can improve liver and spleen infiltration of CML mice. The inhibitor provides a new scheme for overcoming drug resistance, and fills the application blank of SUMOylation modification in CML treatment.

The invention relates to a polypeptide capable of promoting tuft cell proliferation and application of the polypeptide in treatment of inflammatory bowel diseases, in particular to a polypeptide Sjp40-73 derived from schistosome egg protein, and the amino acid sequence of the polypeptide Sjp40-73 is SEQ ID NO.1. The invention further relates to a preparation method of the polypeptide Sjp40-73. The polypeptide can be obtained through methods such as genetic engineering expression or chemical synthesis. In-vitro experiments prove that the peptide can effectively increase the number of tuft cells of intestinal organs of mice; in-vivo experiments further prove that the peptide can relieve mouse inflammatory bowel diseases and can improve corresponding inflammations. The polypeptide prepared by the invention can be applied to medicines, health-care products or food additives for preventing and treating inflammatory enteritis.

The invention discloses a Nur77 methylation site mutation peptide based on structural modification design and application of the Nur77 methylation site mutation peptide in promoting embryo implantation, according to the mutation peptide, arginine at the 346th site of Nur77 is mutated into lysine, and methylation modification of Nur77 is reserved while phosphorylation of Nur77 is inhibited, so that the transcriptional activity of Nur77 is enhanced. It is found that the mutant peptide can promote deciduation of endometrial interstitial cells, remarkably improve deciduation disorder of infertility mice in in-vivo experiments and improve the embryo planting rate of low-fertility mice. Therefore, the mutant peptide is expected to become a new medicine for treating the uterine-derived infertility and has important clinical application value. The invention also relates to a preparation method of the mutant peptide and application of the mutant peptide in a pharmaceutical composition and a treatment method.

Provided are a fully human TSH receptor (TSHR) blocking monoclonal antibody for treating hyperthyroidism, and a preparation method therefor and a use thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and memory single B cells specifically recognizing a TSHR in the peripheral blood of patients having high titers of TSHR blocking antibody (TSH-stimulating blocking antibody, TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells for antibody property screening and validation, to obtain a blocking monoclonal antibody specifically targeting human TSHR. The fully human TSHR blocking monoclonal antibody can specifically bind to the TSHR, has good inhibitory activity in vitro and in vivo experiments, and has broad application prospects in the development of treatment of Graves' diseases.

The invention discloses a nano antibody and a preparation method and application thereof, the nano antibody comprises a heavy chain variable region, the heavy chain variable region comprises CDR1, CDR2 and CDR3, and the amino acid sequence of the heavy chain variable region of the nano antibody comprises SEQ ID NO: 3. The nano antibody provided by the invention is determined as a competitive OTR inhibitor with extracellular treatment potential; in-vitro and in-vivo experiments prove that the nano antibody has a curative effect equivalent to that of atosiban which is widely used clinically, and a new direction is provided for developing effective anti-premature delivery medicines.

The invention provides a recombinant exosome as well as a preparation method and application thereof. The preparation method of the recombinant exosome comprises the following steps: transfecting a target cell with an exosome loaded with nucleic acid molecules, and culturing to prepare the recombinant exosome; the nucleic acid molecule sequentially comprises a promoter sequence, a sequence for coding beta-globin, a 5 '-UTR, a target gene sequence, a sequence for coding alpha-globin, a 3'-UTR and a terminator sequence from the 5'end to the 3 'end. The method not only can be used for producing the recombinant exosome of the specific protein, but also has high flexibility and controllability. The recombinant exosome produced by the preparation method disclosed by the invention shows good stability and biological activity in cell culture and in-vivo experiments, and therapeutic protein can be effectively delivered to target cells. According to the technology, a virus-free and non-integrated treatment method is provided, and common risks in traditional gene therapy are reduced.

The invention provides a traditional Chinese medicine preparation for treating allergic rhinitis and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is prepared from radix asteris, schizonepeta spike, cynanchum paniculatum, perillaseed, spina gleditsiae, cottonrose hibiscus leaf, magnolia flower, semen brassicae, cortex lycii radicis, dendrobe, oroxylum indicum and rhodomyrtus tomentosa; an in-vitro experiment shows that the traditional Chinese medicine preparation can remarkably inhibit the activity of hyaluronidase, also can inhibit the release of beta-HEX in an RBL-2H3 cell degranulation model, reduces the HIS level in a cell supernatant, and effectively improves the morphological abnormality caused by degranulation of RBL-2H3 cells; in-vivo experiments show that the traditional Chinese medicine preparation can significantly reduce behavioral scores of mice suffering from allergic rhinitis, inhibit expression of inflammatory factors TNF-alpha, serum Ig E and OVE-sIg E levels and HA concentration, reduce histopathologic changes caused by allergic rhinitis, effectively repair immune injuries of nasal mucosa of the mice and improve the curative effect of the mice. And a safe and effective new strategy is provided for the treatment of allergic rhinitis.

The invention belongs to the technical field of biological medicine, and provides an engineered extracellular vesicle, a preparation method, application and a drug for targeted repair of blood brain barrier in order to solve the technical problems that an existing repair tool takes effect slowly and is not enough in specificity, and the engineered extracellular vesicle is loaded with Wnt7a-K190A protein. After entering the brain, the engineered extracellular vesicle can be rapidly and specifically combined with a Gpr124 receptor to promote blood brain barrier repair, and in-vivo experiments verify that the engineered extracellular vesicle can promote blood brain repair, so that the engineered extracellular vesicle can be applied to preparation of targeted blood brain barrier repair drugs, becomes a supplement of existing tools, AAV, LNP and the like, and has a wide application prospect. Particularly, the high requirement on the treatment timeliness of central nervous system (injury irreversibility) diseases is met.

The invention provides a polypeptide with an ovary maturation promoting effect and application of the polypeptide in parturition induction of pomfret. The amino acid sequence of the polypeptide is SEQ ID NO: 1. The polypeptide provided by the invention is derived from the GnRH2 gene of the pomfret, and in-vivo experiments prove that the polypeptide can efficiently stimulate the pituitary of the pomfret to secrete gonadotropin, so that the spawning induction time is remarkably shortened, and the spawning rate and the relative spawning amount of parent fish are increased. The polypeptide is strong in species specificity and good in physiological compatibility, does not generate an antibody, avoids side effects of traditional heterologous hormones, is safe and effective, and has a huge potential of being developed into a special spawning induction agent for the pomfret.

The invention relates to the field of biological medicines, in particular to application of hypericin to preparation of a medicine for treating liver cancer. The invention provides application of hypericin in preparation of a medicine for treating liver cancer and a pharmaceutical composition containing the hypericin. The inventor finds that hypericin is used as a traditional Chinese medicine compound, in-vitro experiments prove that hypericin can inhibit liver cancer cell proliferation, inhibit liver cancer cell migration and induce liver cancer cell apoptosis, in-vivo experiments prove that hypericin can significantly inhibit liver tumor cell growth in mice, and it is indicated that hypericin can treat liver cancer. The traditional Chinese medicine composition can be used as a component in medicines for treating liver cancer.

The invention belongs to the field of biological agents, and particularly relates to application of polypeptide HRH and analogues thereof in preparation of drugs for treating pulmonary fibrosis. The amino acid sequence of the polypeptide HRH disclosed by the invention is NH2-His-Arg-His-Thr-Lys-Gln-Arg-His-Thr-Ala-Leu-His-CONH2. An in-vitro experiment proves that the polypeptide HRH can be used for effectively inhibiting pulmonary epithelial cell and fibroblast fibrosis induced by a transforming growth factor and silicosis fibrosis induced by silicon dioxide; in-vivo experiments further prove that the HRH can improve bleomycin-induced pulmonary fibrosis lesion of mice and improve weight loss and death rate of the mice, and meanwhile, the HRH has relatively high safety and no adverse toxic or side effect. The invention also provides an HRH polypeptide analogue which can more effectively inhibit the activation of fibroblasts. The polypeptide HRH prepared by the invention is low in dosage, safe and effective, and provides a potential new medicine for treating pulmonary fibrosis diseases.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of Xianglian intestine decoction in preparation of a medicine for treating ulcerative colitis through a targeted TLR4 / NLRP3 / GSDMD channel. According to the invention, the TLR4 is determined as a key target, and experiments show that the active ingredients in the Xianglian intestine soup and the TLR4 have very strong binding affinity. In-vivo experiments prove that the Xianglian intestine soup down regulates the protein levels of TLR4, NLRP3 and GSDMD-N and the mRNA expression (Plt; 0.05) of IL-1beta and IL-18, so that the pyroptosis is inhibited. Furthermore, the Xianglian intestine decoction inhibits NLRP3 inflammasome activation and GSDMD-mediated pyroptosis by targeting TLR4 so as to relieve UC inflammation and intestinal barrier injury. The invention provides a mechanism insight for the clinical curative effect of the Xianglian intestine decoction for treating ulcerative colitis.

The invention relates to a prostatic cancer targeting CAR (chimeric antigen receptor), a recombinant expression vector containing the same, a lentivirus, CAR-T and application, and belongs to the technical field of tumor immunotherapy. In order to solve the problem that few reports are reported for treating solid tumors by CAR-T cells, the invention provides a CAR for targeting prostatic cancer, the CAR comprises an scFv fragment consisting of VH with an amino acid sequence as shown in SEQ ID NO.2, a hinge region (Gly4Ser) 3 and VL with an amino acid sequence as shown in SEQ ID NO.4, the CAR is connected to a lentiviral expression vector pLV-EF to obtain an expression vector plasmid, and the expression vector plasmid is used for expressing the prostatic cancer. The CAR-T cell is prepared by producing a high-titer lentivirus through a 293T packaging cell line, human primary T lymphocytes infected and activated by the lentivirus are used for preparing the CAR-T cell, in-vivo and in-vitro experiments prove that the CAR-T cell has a specific killing effect on prostatic cancer, and a new treatment thought and means are provided for solid tumor treatment.